Pharmaceuticals
Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane
* On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage * Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries includingItal...
2021-12-29 19:00
5356
DoctorOnCall Offers Free Medical Assistance To Flood Victims
KUALA LUMPUR, Malaysia, Dec. 29, 2021 /PRNewswire/ -- Amidst Malaysia's worst flash flooding following heavy rains over the weekend that displaced tens of thousands of people,Malaysia's first and largest digital health platform, DoctorOnCall, has announced a flood relief medical assistance initia...
2021-12-29 11:30
4964
VISTA Eye Specialist resolved to be a Changemaker and A Force for Good with B Corp Certification.
PETALING JAYA, Malaysia, Dec. 29, 2021 /PRNewswire/ -- VISTA Eye Specialist (VISTA) believes that being one of the leading eye specialists is not just about medical care. "As part of our mission statement, we believe that other than to safely help people see their best, our goal is about changing...
2021-12-29 08:00
3290
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...
2021-12-28 22:00
2620
Muslim-Friendly Malaysia Showcases Healthcare Excellence at Expo 2020 Dubai
DUBAI, UAE, Dec. 28, 2021 /PRNewswire/ -- Malaysia Healthcare, will be showcasing its excellence in healthcare service delivery and providing seamless healthcare journey experiences during Week 14 of Expo 2020 Dubai. From 2nd - 8th January 2022, expo participants can visit the Malaysia Pavilion to...
2021-12-28 15:00
2336
Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS
HONG KONG, Dec. 27, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed. Such clinical trial aims to evalua...
2021-12-28 12:30
2860
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company,announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, smal...
2021-12-28 09:00
2072
CStone announced new drug approval of precision therapy AYVAKIT® (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST)
* AYVAKIT is the first precision therapy approved in Hong Kong, China for the treatment of patients with PDGFRA D842V mutant GIST * This is CStone's fifth NDA approval in Greater China this year SUZHOU, China ,Dec. 28, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...
2021-12-28 08:00
4981
ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron
Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp). The virus is incapable of developing resistance to favipiravir even with long-term exposure on infect...
2021-12-27 21:20
3864
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation (CDE) ofChina's National ...
2021-12-27 21:00
2728
Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19
SUZHOU, China, Dec. 27, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatme...
2021-12-27 20:19
3183
Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-27 18:45
4863
COVID-19 Vaccine Developed by WestVac BioPharma Has High Titer Neutralizing Antibodies Against Omicron
CHENGDU, China, Dec. 24, 2021 /PRNewswire/ -- WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain. The vaccine belongs to the latest fifth generation vaccine technology, targeting the S-RBD protein of the COV...
2021-12-24 19:57
8414
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-12-24 16:51
11556
Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase
SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the "Emerging Company Showcase" that was held earlier this month inNew York. Dr. Guy Rosenthal, Vice President, Head of C...
2021-12-24 16:30
4347
Novavax and SK bioscience Expand Manufacturing Agreement
- Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market GAITHERSBURG, Md., Dec. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializin...
2021-12-24 07:30
4343
Novo Nordisk BASEA office certified Best Place to Work for 2021
KUALA LUMPUR, Malaysia, Dec. 23, 2021 /PRNewswire/ -- Novo Nordisk BASEA office, part of the global healthcare company with more than 95 years of innovation and leadership in diabetes care, has recently achieved the Best Place to Work certification for 2021. During the assessment, the organizati...
2021-12-23 21:37
4507
Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China
BEIJING, Dec. 22, 2021 /PRNewswire/ -- According to Yiling Pharmaceutical's notice onThursday (UTC+8), the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued byChina's National Medical Products Administra...
2021-12-23 11:59
2402
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046
SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 inthe United States. The patient received treatment in ENREACH-Thymic, a phase II, open label, multi-center pivotal...
2021-12-23 09:13
3910
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
SINGAPORE and GUANGZHOU, China and LOS ANGELES, Dec. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surf...
2021-12-23 09:00
4786
Week's Top Stories
Most Reposted
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Klook launches K.ai, an AI agent that manages merchants' back-office operations
[Picked up by 289 media titles]
2026-11-03 14:31
Arrowpoint Investment Partners Selects Arcesium to Scale Asia-Focused Multi-Strategy Platform
[Picked up by 279 media titles]
2026-11-03 09:00OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
54219
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
47191
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
28159
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
18419